INTRODUCTION
Venous thromboembolism (VTE) comprises both: deep vein thrombosis (DVT) and pulmonary embolism (PE) [1, 2] . VTE occurs often with an annual frequency of about 80-180 cases per 100,000 estimated based on population studies [3] [4] [5] . One third of patients with symptomatic VTE is presented as PE, and two thirds as DVT [4] . It is estimated that 63% of all VTE cases are a complication related to a recent hospitalisation [6] . Venous thromboembolism has been cited as a cause of death in up to 10% of patients who died in hospital [7, 8] . In patients undergoing a prophylactic therapy, the rate is signifi cantly lower.
Low molecular weight heparins (LM-WH's) are used to prevent and treat thrombosis. Tests for monitoring LMWH's include anti-factor Xa (anti-FXa), activated partial thromboplastin time (aPTT) and thrombin generation. Anti-FXa is the current gold standard despite LMWH's varying affi nities for FXa and thrombin [9] .
While anti-FXa activity assays are reliable determinants of the concentration of LMWH in the blood [Harris] and are established as a gold standard, they do not necessarily correlate well to the actual eff ect of the drug in vivo: they describe pharmacokinetics rather than pharmacodynamics. Tests of global coagulation such as aPTT and PT-INR are diff erent from anti-FXa activity tests in that they refl ect LMWH's clinical eff ect [10, 11] Th e risk for VTE in major orthopedic surgeryis among the highest for all surgical specialties. Anticoagulant therapy in orthopaedic surgery patients is usually administered in two stadiums: -in the fi rst, with quick anticoagulation the risk of thrombus extension is minimised as well as the risk of fatal PE, and -in the second, prolonged stadium, with long term anticoagulation. On this way recurrence of VTE is prevented and thus long term complications from the disease are reduced such development of post-thrombotic syndrom and chronic hypoxic pulmonary hypertension [12] . It is estimated that approximate risk for the combined symptomatic VTE untreated baseline risk for the fi rst 35 days is 4,3% for all three major orthopedic surgeries (hip and knee replacement, hip fracture). LMWH has become the thromboprophylaxis agent against which newer drugs are compared. For hip and knee replacement LMWHs consistently reduces asymptomatic DVT by 50% combined risk ratio (RR), 0.50; 95% CI, 0.43-0.59). A lot of guidelines include rivaroxaban as as the therapy of choice for prevention of VTE aft er elective arthroplasty since the therapy with rivaroxaban has provided, apart from effi cacy, cost-eff ectiveness [13] [14] [15] . Th e guidelines recommend the continuation of use of rivaroxaban upon the patient's discharge from hospital treatment for additional 35 days for the hip replacement and 14 days for the knee replacement. Rivaroxaban is an oral, direct and specifi c factor Xa inhibitor [16, 17] . It inhibits the free and fi brin-bound factor Xa, inhibits the creation of thrombins and does not infl uence directly aggregation of thrombocytes and thus the primary hemostasis. During the application of rivaroxaban there is no need for the PV (INR) monitoring and its once dailydose of 10mg makes it very simple and practical for application in all adult patients [16, 17] .
In XAMOS, an international, IV phase-noninterventional, observational, openlabel, real-world study designed to assess the safety and eff ectiveness of oral rivaroxaban compared with any other VTE prophylaxis (referred to as SOC) in clinical practice in patients aft er major orthopaedic surgery (including fracture surgery in those countries in which rivaroxaban is approved for this indication), the incidence of symptomatic thromboembolic events was signifi cantly lower in the rivaroxaban group (0.9%) compared with spent, while on the other hand signifi cant savings will be obtained owing to a decrease in the number of inpatient days in hospitals, as well as owing to the fact that regular control examinations of INR and number of blood platelets will not be necessary, which otherwise may amount to EUR 511,248.35annually for the said indication. The authors suggest support for the IV phase of the investigator initiated academic clinical trials with the intention of gaining security and personal experiences of doctors who use rivaroxaban in clinical practice.
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Th e RECORD 1 (n = 4541) [19] and RECORD 2 (n = 2509) [20] programme trials were multicentre, prospective, double-blind, parallel-group design RCTs comparing rivaroxaban with enoxaparin for the prevention of VTE aft er total hip replacement surgery. In RECORD 1, rivaroxaban was administered at a dosage of 10 mg once daily for 35 days starting on the day of surgery. Enoxaparin was administered at a dosage of 40 mg starting 1 day before surgery and for 35 days thereaft er. For this study, the manufacturer reported a statistically signifi cant diff erence in the incidence of the composite primary endpoint between rivaroxaban and enoxaparin based on a 'modifi ed' intention to treat (MITT) analysis. Th e primary endpoint occurred in 1.1% of the rivaroxaban group compared with 3.7% of the enoxaparin group; relative risk reduction (RRR) was 70% (95% [CI] 49 to 82, p < 0.001) [20] .
In Serbia, the anticoagulant therapy with unfractionated heparin (UFH), low molecular weight heparin (LMWH) and warfarin are standard of care treatment for VTE aft er orthopedic surgery Institute for Orthopaedic Surgery "Banjica", Belgrade, Serbia doctors use Th romboembolism Prophylaxis Guide prepared and adopted in Institute [21] .
THE AIM
Th e aim of this study is to demonstrate costeff ectiveness of the new therapy with rivaroxaban versus conventional in VTE prophylaxis for patients undergoing elective hip or knee replacement surgery.
METHODS
Th is paper is a part of the academic IV phase pharmacoecconomic study using extrapolation datas, done in Serbia as single center expirience of Institute for Orthopaedic Surgery "Banjica" . With at least 4600 expected elective hip replacement and 2300 expected elective knee replacement surgeries per year in Serbia, patients who are under the same age and sex are comparable with the patients included in studies RECORD 1 and RECORD 2 [19, 20] .
Information on drug prices, basic pharmacological characteristics, and on services of health institutions, are taken from the List of Drugs and Pricelist of the Republic Health Insurance Fund [22] , as well as the Th romboembolism Prophylaxis Guide of the Institute "Banjica" [21] . Th e Incremental costeff ectiveness ratio (ICER) and Cost-utility analysis (CUA) have also been used in relation to the Quality-adjusted life-year (QALY). Furthermore, in the calculation the proposed price of a defi ned daily dose (DDD) of rivaroxaban was 3.36 EUR.
In Serbia, LMWH's are most oft en used in orthopaedic surgery and has been included into the calculation. Diff erence in price per day of the therapy with low molecular weight heparin is relatively small, so we believe that our applied model may be approximated to an application of other low molecular weight heparins in the prevention of VTE in elective hip and knee surgeries.
In the statistical data processing, for the purpose of authenticity and applicability in "everyday practice" the most used therapeutic scheme has been used, including the frequency of INR controls and the usual number of days of hospital stay.
Pharmacoeconomic model is divided into three modules: -prophylaxis period, -extrapolation period, -late complications period.
Prophylaxis period
Even though in the approved indications for the application of rivaroxaban the proposed dosage scheme is 6-8 hours aft er the surgical intervention (Xarelto®, Bayer) [17] , during the preparation of the pharmacoeconomic study and with the purpose of making it applicable on the territory of Serbia, we have used recommendations provided in the expert opinion which represents an integral part of the documentation of the Application to include the medicine in the Reimbursement List (Offi cial Gazette of the Republic of Serbia) [22] : LMWH administered a day before and 2 days aft er the surgery, from day 3, including warfarin and continuation of the therapy with the same up to 14 days from the knee surgery, i.e. up to 35 days from the hip surgery. Application of warfarin, determining the dose as well as monitoring of INR are, in line with the approved protocols, followed by regular controls of INR and number of thrombocytes.
Risk of VTE during the prophylaxis period has been estimated based on data from RECORD 1 and RECORD 3 pivotal phase III studies, for patients undergoing elective hip replacement surgery (RECORD 1) [19] or knee replacement surgery (RECORD 3) [23] .
With rivaroxaban there is no need for INR monitoring, and according to internal hospital protocols, the introduction of rivaroxaban could reduce the number of days of hospital stay: 1. elective knee replacement surgery --> reduction of in hospital days from 14 to 10 (total of 4 days) 2. elective hip replacement surgery --> reduction of in hospital days from 21 to 14 (total of 7 days).
Post-prophylaxis period (extrapolation period)
In order to assess the probability to develop a symptomatic venous thromboembolism aft er a non-treated asymptomatic VTE (observed in a period of 90 days aft er the termination of prophylaxis). It has been used the publication Quinlan et al. (2004),-Mid-term complications.
Late complications period
In order to assess recurrence of VTE, observed over a monitoring period of 5 years, data has been used from Prandoni et al. (1997) [13] .
Furthermore, Quality adjusted life years (QALYs, quality of life during the monitoring period) has been estimated based on a statistical model which included the probability of occurrence of venous thromboembolism, pulmonary embolism, postthrombotic syndrome, recurrent VTE.
In favour of proper classifi cation of costs of treatment, are shown in the tables all costs following procedures burdening certain therapeutic protocols. Also, in the absence of implementation of the Diagnosis-related group (DRG), shows the cost of the medical staff who work in the department.
RESULTS
Th e data listed in the tables were obtained by extrapolation method data from the register: Additional days of hospitalisation, Costs of treatment of DVT/PE during the prophylaxis application [18] , Costs of treatment of recurrent VTE, during the period of 1 year [11] .
Th e use of rivaroxaban may reduce the costs of the Republic Health Insurance Fund by 71.49 EUR per patient on an annual level, with simultaneous improvement of the quality of life. Needlessness of INR monitoring and determining the number of thrombocytes, lower number of days of hospitalisation (7 days), lower costs of treatment of DVT/PE during the prophylaxis application and of recurrent VTE,makes application of rivaroxaban more cost-eff ective than standard prophylaxis in one year period.
Th e use of rivaroxaban may reduce the costs of the Republic Health Insurance Fund by 75.84 EUR per patient at a fi ve year level, with simultaneous improvement of the quality of life. Needlessness of INR monitoring and determining the number of thrombocytes, lower number of days of hospitalisation (7 days), lower costs of treatment of DVT/PE during the prophylaxis application and of recurrent VTE, makes application of rivaroxaban more cost-eff ective than standard prophylaxis in fi ve years period. the cost of a hospital day. Th is is very important due to changes of the payment system according to the Diagnostically related groups (DRG) which is expected to be implemented in the Republic Health Insurance Fund in the coming period.
A daily cost of income for the medical staff at the department per patient is modelled according to the Institute for Orthopaedic Surgery "Banjica".
Considering the reduction of inhospital days aft er elective knee replacement surgery from 14 to 10 (4 days total) and the reduction of in-hospital aft er elective hip replacement surgery from 21 to 14 (7 days total), additional saving of 75.50 i.e. 132.00 EUR per patient which, at the total annual level, represents savings of 173,588.50 EUR for patients with knee replacement and 607,559.70 EUR for patients with hip replacement, could lead to total saving for the Republic Health Insurance Fund of 781,148.20 EUR annually.
Incremental cost eff ectiveness ratio (ICER) ICER=C XR -C SP/E XR-E SP=ΔC/ΔE
Hip replacement surgery C XR-costs for patients treated with rivaroxaban for the period of 1 year C SP-costs for patients treated with current prophylaxis for the period of 1 year E XR-QАLY years of life for patients treated with rivaroxaban E SP-QALY years of life for patients treated with current prophylaxis ICER=129.70-201.20/7,969-7,963 ICER=-71.50/0,006=-11,916.70 EUR/QALY Knee replacement surgery C XR-costs for patients treated with rivaroxaban for the period of 1 year C SP-costs for patients treated with current prophylaxis for the period of 1 year E XR-QАLY years of life for patients treated with rivaroxaban E SP-QALY years of life for patients treated with current prophylaxis ICER=62.97-142.30/7,985-7,971 ICER=-79.33/0,014=-5,666.40 EUR/QALY Considering that in both cases C XR <C SP and E XR>E SP, we come to a conclusion that rivaroxaban is dominant, i.e. less costly and more eff ective than current prophylaxis. Th e incremental cost-eff ectiveness ratio has shown that costs of therapy with rivaroxaban are signifi cantly lower than with the current prophylaxis with simultaneous improvement in the quality of life for patients treated with rivaroxaban.
COST-UTILITY ANALYSIS (CUA)
From the table 7 it can be seen that the strategy for introduction of rivaroxaban in the therapy is highly cost-eff ective as it could result in savings of 12,358.90 EUR per QALY during a one year period.
From the table 8 it can be seen that the strategy for introduction of rivaroxaban in the therapy is highly cost-eff ective considering it could result in savings of 5,998.30 EUR per QALY during a one year period.
INDIRECT COSTS
It can been assumed that a certain percentage of patients belong to the working population, so the VTE complications surely lead to extension of sick leaves paid by the funds (the Republic Health Insurance Fund), as well as to previous and subsequent loss in productivity which is not to be dismissed from the socioeconomic aspect, both of the patient as of the society as a whole. Th e introduction of rivaroxaban in the therapy will enable patients to receive more conformable oral therapy, with significant savings. Th is will be obtained owing to a decrease in the number of inpatient days in hospitals, as well as owing to the fact that regular control examinations of INR and number of blood platelets will not be necessary, which otherwise may amount to 511,248.40 EUR an- Indirect and non-material (Intangible) costs such as sick leaves paid by the health insurance funds, loss in productivity, pain, disability, low mobility, sleep disorders, reaction, concentration, memory, fear, depression, anxiety and apathy, confl icts, addiction, also aff ect both the cost of further treatments, and the quality of life of patientsand their families.
NON-MATERIAL (INTANGIBLE) COSTS

CONCLUSION
Venous thromboembolism is oft en clinically unobservable, showing the fi rst symptoms only aft er the patient has been discharged from the hospital, owing to which symptoms may not be recognized in time and serious complications may arise aft er hip or knee replacement surgery.
With rivaroxaban there is no need for INR monitoring, and according to internal hospital protocols, the introduction of rivaroxaban could reduce the number of days of hospital stay With at least 4600 expected elective hip replacement 2300 and expected elective knee replacement surgeries per year in Serbia and observed during the fi rst year period, application of rivaroxaban would save the Republic Health Insurance Fund 511,248.40 EUR. Savings achieved at a fi ve year level (long-term complications) would reach 563,874.90 EUR.
Th e introduction of rivaroxaban in the therapy enabled patients to receive more conformable oral therapy.
Th is analysis demonstrated cost-effectiveness of the new therapy with rivaroxaban versus conventional in VTE prophylaxis for patients undergoing elective hip or knee replacement surgery.
Th e authors suggest support for the IV phase of the investigator initiated academic clinical trials with the intention of gaining security and personal experiences of doctors who use rivaroxaban in clinical practice.
